Sam Brusco, Associate Editor05.21.24
WearLinq, a provider of wearable health monitoring and diagnosis solutions, has acquired AMI Cardiac Monitoring, an independent diagnostic testing facility with expertise in ambulatory cardiac monitoring.
WearLinq said the acquisition will allow it to offer expansive clinical services across all 50 states and give more access to its eWave six-lead wearable ECG monitor, which recently gained U.S. Food and Drug Administration (FDA) 510(k) clearance.
The eWave six-lead ECG device provides a detailed, multidimensional view of the heart, with P-wave visibility and ECG clarity. It works with a smartphone to allow long-term monitoring, with recharging in an AirPods-like case. It magnetically attaches to WearLinq’s skin-like adhesive patches.
“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” said Konrad Morzkowski, CEO of WearLinq. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”
The minimally intrusive eWave lets patients maintain their lifestyle while continuously monitoring cardiac health. It’s also integrated with a cloud platform to ensure near real-time data analysis and actionable insights.
“This is just the beginning; we have an exciting pipeline of AI products to further empower patients and providers, as well as take our reach beyond cardiac monitoring,” added Morzkowski. “We are dedicated to continuous innovation and expanding our impact across the healthcare spectrum.”
This announcement follows a successful close of $6.7 million in early-stage investment from SpringTide, Social Impact Capital, Amino Capital, Berkeley Catalyst Fund, Human Longevity and angels from iRhythm and AliveCor.
WearLinq said the acquisition will allow it to offer expansive clinical services across all 50 states and give more access to its eWave six-lead wearable ECG monitor, which recently gained U.S. Food and Drug Administration (FDA) 510(k) clearance.
The eWave six-lead ECG device provides a detailed, multidimensional view of the heart, with P-wave visibility and ECG clarity. It works with a smartphone to allow long-term monitoring, with recharging in an AirPods-like case. It magnetically attaches to WearLinq’s skin-like adhesive patches.
“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” said Konrad Morzkowski, CEO of WearLinq. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”
The minimally intrusive eWave lets patients maintain their lifestyle while continuously monitoring cardiac health. It’s also integrated with a cloud platform to ensure near real-time data analysis and actionable insights.
“This is just the beginning; we have an exciting pipeline of AI products to further empower patients and providers, as well as take our reach beyond cardiac monitoring,” added Morzkowski. “We are dedicated to continuous innovation and expanding our impact across the healthcare spectrum.”
This announcement follows a successful close of $6.7 million in early-stage investment from SpringTide, Social Impact Capital, Amino Capital, Berkeley Catalyst Fund, Human Longevity and angels from iRhythm and AliveCor.